140 likes | 162 Views
Explore the benefit of surgical resection for metachronous liver metastases from stomach cancer. Evaluate overall survival rates and clinicopathologic characteristics to highlight the potential benefits. Research conducted at Yonsei University College of Medicine from 1997 to 2011.
E N D
Surgical resection of metachronous liver metastases from advanced gastric cancer Sung Hyun Kim,Dai Hoon Han, Gi Hong Choi, Kyung Sik Kim, JinSub Choi Department of Hepatobiliary and Pancreatic Surgery, Yonsei University College of Medicine
Introductions • Metachronousliver metastases from stomach cancer • Metachronous liver metastases are observed in about 50% of stomach cancer patients during the course of the disease. • However, the role of surgical therapy in patients with metachronous liver metastases from stomach cancer is still controversial. Yonsei University College of Medicine
Introductions • Aim of study • To evaluate benefit of surgical resection for metachronous liver metastasis from stomach cancer Yonsei University College of Medicine
Methods Period : January 1997 ~ December 2011 Materials : Metachronous and solely liver metastases patients who underwent radical gastrectomy due to stomach cancer Exclusion criteria :Early gastric cancerMultiple liver metastases (>3) No treatment patients Primary end point :Overall survival (OS) Yonsei University College of Medicine
Methods Exclusion criteria 1. Early gastric cancer 2. Multiple liver metastases 3. No treatment patients Yonsei University College of Medicine
Results Basal characteristics
Results Basal characteristics
Results Clinicopathologic characteristics according to treatment modality
Results Clinicopathologic characteristics according to treatment modality
Results Overall survival rate according to treatment modality P < 0.001 Surgery Median 29.1m CTx. Median 17.8m Yonsei University College of Medicine
Results Association of candidate prognostic variables with survival
Conclusions • Surgical resection of metachronous liver metastases • Can improve patients’ survival comparing to chemotherapy Yonsei University College of Medicine